Cargando…

Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)

PURPOSE: Recombinant activated factor VII (rFVIIa; NovoSeven(®) RT; Novo Nordisk A/S, Bagsvaerd, Denmark) is approved in the United States for the treatment of bleeding and perioperative management in congenital hemophilia with inhibitors (CHwI), acquired hemophilia (AH), congenital factor VII (FVII...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajpurkar, Madhvi, Croteau, Stacy E, Boggio, Lisa, Cooper, David L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757140/ https://www.ncbi.nlm.nih.gov/pubmed/31572039 http://dx.doi.org/10.2147/JBM.S219573

Ejemplares similares

Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage
por: Aggarwal, Anita, et al.
Publicado: (2004)

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021)

Efficacy of recombinant activated factor VII (rFVIIa; NovoSeven(®)) in obstetrical haemorrhagic shock
por: Sobieszczyk, S, et al.
Publicado: (2003)

Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients
por: Ng, Heng Joo, et al.
Publicado: (2006)

Nebulised recombinant activated factor VII (rFVIIa) does not attenuate the haemorrhagic effects of blast lung injury
por: Smith, Jason E, et al.
Publicado: (2019)

Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience
por: Shah, Nurfatin Mohd, et al.
Publicado: (2018)

Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann’s thrombasthenia
por: Poon, Man-Chiu
Publicado: (2007)

Recombinant activated factor VII (rFVIIa-NovoSeven(®)-NovoNordisk) treatment of bleeding complications in intensive care unit
por: Bonadona, A, et al.
Publicado: (2002)

Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy
por: Nicosia, Dario, et al.
Publicado: (2019)

Bioengineering of rFVIIa Biopharmaceutical and Structure Characterization for Biosimilarity Assessment
por: Montacir, Othman, et al.
Publicado: (2018)

Recombinant Activated Factor VII (rFVIIa) in the Management of Major Obstetric Haemorrhage: A Case Series and a Proposed Guideline for Use
por: Bomken, Charlotte, et al.
Publicado: (2009)

Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors
por: Milošević, Danko, et al.
Publicado: (2014)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
por: Linari, Silvia, et al.
Publicado: (2020)

Recombinant activated coagulation factor VII (rFVIIa) as an adjunctive hemostatic therapy in patients with multiple system organ failure and acute upper gastrointestinal bleeding
por: Milanov, S, et al.
Publicado: (2003)

Regional variation of the off-licence use of rFVIIa for patients with uncontrolled haemorrhage in England
por: Spivey, MH, et al.
Publicado: (2010)

Efficacy of activated recombinant factor VII (rFVIIa; NovoSeven(®)) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial
por: Thabut, D, et al.
Publicado: (2004)

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban‐treated patients in vitro
por: Schultz, Nina H., et al.
Publicado: (2017)

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
por: Schultz, Nina Haagenrud, et al.
Publicado: (2017)

Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency
por: Rajpurkar, Madhvi, et al.
Publicado: (2018)

Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood
por: Haidl, Harald, et al.
Publicado: (2019)

Case report: Intraoperative thrombosis cardiac arrest in extended right hepatectomy involving use of local haemostatic agent in intraoperative cell salvage (ICS) and administration of recombinant activated factor VII (rFVIIa)
por: Kyang, Lee S., et al.
Publicado: (2019)

Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors—An In Vitro Study
por: Schultz, Nina Haagenrud, et al.
Publicado: (2021)

Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) – a review of a new treatment paradigm
por: Heslet, Lars, et al.
Publicado: (2012)

Use of recombinant factor VIIa (rFVIIa) as pre-hospital treatment in a swine model of fluid percussion traumatic brain injury
por: Kim, Bobby, et al.
Publicado: (2014)

Treatment of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus Patient With Local Pulmonary Administration of Factor VIIa (rFVIIa): A Case Report
por: Alabed, Iehab B.
Publicado: (2014)

Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report
por: Ma, Hongbing, et al.
Publicado: (2021)

Thromboelastometry as an Ancillary Tool for Evaluation of Coagulation Status after rFVIIa Therapy in a Pregnant Woman with Severe Hypoproconvertinemia—A Case Series and Review of the Literature
por: Krzyżanowski, Arkadiusz, et al.
Publicado: (2022)

A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost–utility analysis
por: Saiyarsarai, Parisa, et al.
Publicado: (2021)

Efficacy of idarucizumab, prothrombin complex concentrate (PCC) and activated PCC to reverse the anticoagulatory potential of dabigatran in a porcine polytrauma model
por: Honickel, M, et al.
Publicado: (2015)

Characterization of Aldosterone-producing Cell Cluster (APCC) at Single-cell Resolution
por: Iwahashi, Norifusa, et al.
Publicado: (2022)

Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial
por: Kluger, Yoram, et al.
Publicado: (2007)

FRI166 Characterization of Aldosterone-producing Cell Cluster (APCC) At Single-cell Resolution
por: Iwahashi, Norifusa, et al.
Publicado: (2023)

A randomised, placebo-controlled, double-blind study to investigate the efficacy and safety of rFVIIa as adjunctive therapy for control of bleeding in patients with severe blunt trauma: a re-analysis following the exclusion of early (< 48 hours) deaths
por: Rossaint, R, et al.
Publicado: (2005)

Prothrombin complex concentrate (PCC) for treatment of trauma-induced coagulopathy: systematic review and meta-analyses
por: Hannadjas, Ioannis, et al.
Publicado: (2023)

Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models
por: Ghosh, Subhajit, et al.
Publicado: (2021)

Tissue factor/FVIIa activates Bcl-2 and prevents doxorubicin-induced apoptosis in neuroblastoma cells
por: Fang, Jun, et al.
Publicado: (2008)

Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab
por: Valls, Raquel, et al.
Publicado: (2023)

Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
por: Tao, Jing, et al.
Publicado: (2018)

PB2651: A COMPARISON OF TIME TO TREATMENT WITH PROTHROMBIN COMPLEX CONCENTRATE: REMOTE OR POINT OF CARE STORAGE OF PCC
por: Bonney, Samantha, et al.
Publicado: (2023)

Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience
por: Han, Myung Hee, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4e5kaspndc5rdbtmf4e4o4q216